becotatug vedotin

Overview

Becotatug vedotin (MRG003) is an antibody-drug conjugate (ADC) targeting EGFR, delivering a cytotoxic payload to EGFR-overexpressing tumor cells. It has shown activity in R/M nasopharyngeal carcinoma (NPC) in patients who had received prior platinum chemotherapy and anti-PD-1/PD-L1 therapy.

Evidence in the corpus

• In R/M NPC post platinum + anti-PD-1 (NCT05126719, n=61): ORR 39.3% (dose level 1) / 55.2% (dose level 2); separate randomized study reported ORR 30.2% vs 11.2% for standard chemotherapy; grade ≥3 TRAE 45.3% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.